InSilico Medicine Cayman TopCo's shares have rocketed over 60% in a month, forcing investors to scrutinize whether its AI-driven drug discovery promise can justify the momentum, especially against a backdrop of persistent losses and a negative book value.
After a period of significant volatility, Neogen Corporation (NEOG) is showing signs of a sustainable operational turnaround under new leadership, with its latest quarterly results beating expectations and prompting a rare guidance upgrade.
Business Facilities magazine has named North Carolina its 'State of the Year' for business climate and economic development, the state's third such win in six years, following a surge of multi-billion dollar investments from tech and manufacturing giants.
Hercules Capital (HTGC), a key lender to venture-backed companies, appears significantly undervalued by traditional metrics. With shares trading at a discount to intrinsic value and below peer multiples, the market may be overlooking its strategic role and earnings potential.
The French government has secured parliamentary approval for its 2026 budget, ending a months-long impasse after Prime Minister Sebastien Lecornu weathered a series of no-confidence motions. The passage followed strategic concessions to the Socialist party, a key swing bloc.
In a significant shift, Harvard College reports a nearly 7-point decline in 'A' grades awarded last semester, marking the first tangible result of a faculty-led campaign to restore meaning to academic evaluations and combat rampant grade inflation.
Despite a post-earnings slump and near 52-week lows, Abbott Laboratories' resilient medical device unit, strategic expansion in diabetes care, and a landmark acquisition in cancer diagnostics paint a promising long-term picture for this Dividend Aristocrat.
While AI's role in headline-grabbing discoveries like AlphaFold is celebrated, Anthropic is forging a new path. Through partnerships with the Allen Institute and HHMI, the company is embedding Claude AI into the unglamorous, time-consuming groundwork of research—betting that efficiency gains in data analysis and coordination will compress decades of scientific progress.
After months of political gridlock and a series of no-confidence votes, France's parliament is poised to adopt the contentious 2026 budget. The survival of Prime Minister Sebastien Lecornu's government hinges on Monday's vote, marking a critical juncture for the nation's fiscal and political stability.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
The biotech company Grail has formally submitted its Galleri test for FDA premarket approval, a critical step that could unlock widespread insurance reimbursement and integrate the multi-cancer screening tool into mainstream preventive care.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Ardelyx, Inc. (NASDAQ: ARDX) has received significant analyst upgrades, with TD Cowen and Jefferies raising price targets ahead of the company's fourth-quarter results. The optimism centers on the commercial trajectory of its flagship drug, tenapanor, for gastrointestinal and kidney conditions.
Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.
Twist Bioscience kicks off fiscal 2026 with robust growth, reporting a 17% year-over-year revenue increase to $103.7 million. The company credits its semiconductor-based DNA synthesis platform and surging demand from AI-enabled drug discovery programs as key drivers, while reiterating its path to adjusted EBITDA breakeven within the year.
After a protracted political standoff, France's long-delayed 2026 budget is set for adoption, granting Prime Minister Sebastien Lecornu a hard-won victory but leaving President Macron's domestic reform agenda in limbo ahead of the 2027 election.
Revvity (NYSE: RVTY) surged past fourth-quarter expectations and issued an upbeat 2026 outlook, driven by robust demand in its diagnostics division. The medical equipment maker's performance highlights a sector-wide resilience despite ongoing softness in academic research funding.
IQVIA Holdings Inc. (NYSE:IQV) boasts a robust 20% Return on Equity, significantly outpacing its industry. However, a deeper look reveals a heavy reliance on debt, prompting analysts to weigh impressive profitability against underlying financial risk.
A wave of insider buying at 908 Devices Inc. has caught the market's attention, signaling potential optimism among those who know the company best. While not a guaranteed predictor, such coordinated activity often precedes significant corporate developments.
While stocks priced between $10 and $50 can appear to offer an attractive balance of accessibility and maturity, their low price tags can sometimes mask underlying vulnerabilities. We examine three such companies where caution may be prudent.
